Do you want to read an article? Please log in or register.
Eosinophilic Granulomatosis with Polyangiitis: clinical predictors of long-term asthma severity
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
J Allergy Clin Immunol.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H
doi: 10.1016/j.jaci.2018.09.033.
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
COMMENTED
Consequences of long-term OCS therapy and its side effects in severe asthma in adults - A focused review of the impact data in the literature
Eur Respir J.
Volmer T, Effenberger T, Trautner C, Buhl R
doi: 10.1183/
RECOMMENDED
Asthma
Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature
Eur Respir J.
Volmer T, Effenberger T, Trautner C, Buhl R
doi: 10.1183/13993003.
RECOMMENDED
Asthma
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
Lancet Respir Med.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators
doi: 10.1016/S2213-2600
Asthma
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma
Respir Res.
Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist Å, Colice G
doi: 10.1186/s12931-020-01541-7.
RECOMMENDED
Asthma
Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function
Respir Med.
Mansur AH, Srivastava S, Sahal A
doi: 10.1016/j.rmed.2018.08.005.
RECOMMENDED
AsthmaFurther Publications
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M
doi: 10.1016/S2213-2600(21)00322-2
Asthma
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Biologics
Haldar P
doi: 10.2147/BTT.S93954.